Piqué et al.10pointed out that CELF2 was targeted by promoter hypermethylation‐associated transcriptional silencing in human cancer, and the presence of CELF2 hypermethylation was associated with shorter overall survival in patients with breast cancer. Here, CELF2 is linked to breast carcinoma.